OncRef

Clinical Trial: NCT04895358

Study of Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy for HR+/HER2- Locally Recurrent Inoperable or Metastatic Breast Cancer (MK-3475-B49/KEYNOTE-B49)

Status:

ACTIVE NOT RECRUITING

Phase:

Phase 3

Lead Sponsor:Merck Sharp & Dohme LLC
Information Provided By:Merck Sharp & Dohme LLC
Last Update Posted:2026-07-22

Study Overview

Brief Summary

The safety and efficacy of pembrolizumab plus the investigator's choice of chemotherapy will be assessed compared to placebo plus the investigator's choice of chemotherapy in the treatment of chemotherapy-candidate hormone receptor-positive, human epidermal growth factor receptor 2-negative (HR+/HER2-) locally recurrent inoperable or metastatic breast cancer.

The primary hypotheses are that the combination of pembrolizumab and chemotherapy is superior to placebo and chemotherapy in regards to Progression-Free Survival (PFS) in participants with programmed cell death-ligand 1 (PD-L1) combined positive score (CPS) ≥1.

Prior to protocol amendment 7, participants who discontinued pembrolizumab/placebo with SD or better and subsequently experienced disease progression may have been eligible for up to 17 additional administrations of pembrolizumab if, upon unblinding, they were found to have received pembrolizumab, at the same dose and schedule used for the initial treatment period.

Official Title

A Randomized, Double-blind, Placebo-controlled, Phase 3 Study of Pembrolizumab Plus Chemotherapy Versus Placebo Plus Chemotherapy for the Treatment of Chemotherapy-Candidate Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative (HR+/HER2-) Locally Recurrent Inoperable or Metastatic Breast Cancer (KEYNOTE-B49)

Conditions

Breast Neoplasms

Intervention / Treatment

  • Biological: pembrolizumab
  • Drug: paclitaxel
  • Drug: nab-paclitaxel
  • Drug: liposomal doxorubicin
  • Drug: capecitabine
  • Drug: normal saline
  • Drug: dextrose

Other Study ID Numbers

  • 3475-B49
  • MK-3475-B49
  • KEYNOTE-B49
  • 2023-506752-24-00
  • U1111-1294-3354
  • jRCT2051210049
  • PHRR210721-003751
  • 2020-005407-38
  • 2023

Start Date (Actual)

2021-06-18

Primary Completion Date (Actual)

2026-04-24

Study Completion Date (Estimated)

2027-12-18

Enrollment (Actual)

342

Study Type

Interventional

Phase

Phase 3